Beyondspring Inc BYSI
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-03-09 |
| Shares Out. | 41,120,000 |
| Website | beyondspringpharma.com/en/ ↗ |
| Phone | 16465284184 |
| Employees | 44 |
| Net Income | -$6.7M |
| Free Cash Flow | -$18.8M |
| Total Assets | $18.4M |
| Total Liabilities | $48.8M |
| Equity | -$30.4M |
About Beyondspring Inc
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
Beyondspring Inc is a publicly traded company under the ticker symbol BYSI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2024-06-01)